The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it.
Analyzing Marinus Pharmaceuticals Inc’s Short Interest
Marinus Pharmaceuticals Inc's (NASDAQ:MRNS) short percent of float has risen 9.74% since its last report. The company recently reported that it has 1.23 million shares sold short, which is 3.83% of all regular shares that are available for trading.
Truist Securities Maintains Buy on Marinus Pharmaceuticals, Raises Price Target to $50
Truist Securities analyst Joon Lee maintains Marinus Pharmaceuticals (NASDAQ:MRNS) with a Buy and raises the price target from $35 to $50.
SVB Leerink Maintains Outperform on Marinus Pharmaceuticals, Lowers Price Target to $27
SVB Leerink analyst Marc Goodman maintains Marinus Pharmaceuticals (NASDAQ:MRNS) with a Outperform and lowers the price target from $30 to $27.